3hnb

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
{{STRUCTURE_3hnb| PDB=3hnb | SCENE= }}
+
==Factor VIII Trp2313-His2315 segment is involved in membrane binding as shown by crystal structure of complex between factor VIII C2 domain and an inhibitor==
-
===Factor VIII Trp2313-His2315 segment is involved in membrane binding as shown by crystal structure of complex between factor VIII C2 domain and an inhibitor===
+
<StructureSection load='3hnb' size='340' side='right' caption='[[3hnb]], [[Resolution|resolution]] 1.15&Aring;' scene=''>
-
{{ABSTRACT_PUBMED_20089867}}
+
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[3hnb]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3HNB OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3HNB FirstGlance]. <br>
 +
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=768:(2R)-1-(2,4-DICHLOROPHENOXY)-3-[(2E)-2-IMINO-3-(2-PIPERIDIN-1-YLETHYL)-2,3-DIHYDRO-1H-BENZIMIDAZOL-1-YL]PROPAN-2-OL'>768</scene></td></tr>
 +
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">F8 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3hnb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3hnb OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3hnb RCSB], [http://www.ebi.ac.uk/pdbsum/3hnb PDBsum]</span></td></tr>
 +
</table>
 +
== Disease ==
 +
[[http://www.uniprot.org/uniprot/FA8_HUMAN FA8_HUMAN]] Defects in F8 are the cause of hemophilia A (HEMA) [MIM:[http://omim.org/entry/306700 306700]]. A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. Note=Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non-functional; i.e. the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.<ref>PMID:3012775</ref> <ref>PMID:3122181</ref> <ref>PMID:2833855</ref> <ref>PMID:2835904</ref> <ref>PMID:2499363</ref> <ref>PMID:2506948</ref> <ref>PMID:2510835</ref> <ref>PMID:2495245</ref> <ref>PMID:2498882</ref> <ref>PMID:2104766</ref> <ref>PMID:2105106</ref> <ref>PMID:1973901</ref> <ref>PMID:2105906</ref> <ref>PMID:2106480</ref> <ref>PMID:2107542</ref> <ref>PMID:1908817</ref> <ref>PMID:1908096</ref> <ref>PMID:1851341</ref> <ref>PMID:1356412</ref> <ref>PMID:1639429</ref> <ref>PMID:1349567</ref> <ref>PMID:1301194</ref> <ref>PMID:1301932</ref> <ref>PMID:1301960</ref> <ref>PMID:8449505</ref> <ref>PMID:8322269</ref> <ref>PMID:7579394</ref> <ref>PMID:7794769</ref> <ref>PMID:7759074</ref> <ref>PMID:8644728</ref> <ref>PMID:8639447</ref> <ref>PMID:8759905</ref> <ref>PMID:9029040</ref> <ref>PMID:9326186</ref> <ref>PMID:9341862</ref> <ref>PMID:9886318</ref> <ref>PMID:9450898</ref> <ref>PMID:10215414</ref> <ref>PMID:9603440</ref> <ref>PMID:9452104</ref> <ref>PMID:9792405</ref> <ref>PMID:9829908</ref> <ref>PMID:9569180</ref> <ref>PMID:9569189</ref> <ref>PMID:10554831</ref> <ref>PMID:10338101</ref> <ref>PMID:10408784</ref> <ref>PMID:10404764</ref> <ref>PMID:10910910</ref> <ref>PMID:10910913</ref> <ref>PMID:10691849</ref> <ref>PMID:10886198</ref> <ref>PMID:10800171</ref> <ref>PMID:10896236</ref> <ref>PMID:10612839</ref> <ref>PMID:11410838</ref> <ref>PMID:11298607</ref> <ref>PMID:11442643</ref> <ref>PMID:11442647</ref> <ref>PMID:11554935</ref> <ref>PMID:11748850</ref> <ref>PMID:11341489</ref> <ref>PMID:12351418</ref> <ref>PMID:12406074</ref> <ref>PMID:12199686</ref> <ref>PMID:11857744</ref> <ref>PMID:12203998</ref> <ref>PMID:12325022</ref> <ref>PMID:11858487</ref> <ref>PMID:12195713</ref> <ref>PMID:12930394</ref> <ref>PMID:12871415</ref> <ref>PMID:12614369</ref> <ref>PMID:15682412</ref> <ref>PMID:15810915</ref> <ref>PMID:16805874</ref> <ref>PMID:18184865</ref> <ref>PMID:21371196</ref>
 +
== Function ==
 +
[[http://www.uniprot.org/uniprot/FA8_HUMAN FA8_HUMAN]] Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.
 +
== Evolutionary Conservation ==
 +
[[Image:Consurf_key_small.gif|200px|right]]
 +
Check<jmol>
 +
<jmolCheckbox>
 +
<scriptWhenChecked>select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/hn/3hnb_consurf.spt"</scriptWhenChecked>
 +
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
 +
<text>to colour the structure by Evolutionary Conservation</text>
 +
</jmolCheckbox>
 +
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/chain_selection.php?pdb_ID=2ata ConSurf].
 +
<div style="clear:both"></div>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Factor VIII (FVIII) plays a critical role in blood coagulation by forming the tenase complex with factor IXa and calcium ions on a membrane surface containing negatively charged phospholipids. The tenase complex activates factor X during blood coagulation. The carboxyl-terminal C2 domain of FVIII is the main membrane-binding and von Willebrand factor-binding region of the protein. Mutations of FVIII cause hemophilia A, whereas elevation of FVIII activity is a risk factor for thromboembolic diseases. The C2 domain-membrane interaction has been proposed as a target of intervention for regulation of blood coagulation. A number of molecules that interrupt FVIII or factor V (FV) binding to cell membranes have been identified through high throughput screening or structure-based design. We report crystal structures of the FVIII C2 domain under three new crystallization conditions, and a high resolution (1.15 A) crystal structure of the FVIII C2 domain bound to a small molecular inhibitor. The latter structure shows that the inhibitor binds to the surface of an exposed beta-strand of the C2 domain, Trp(2313)-His(2315). This result indicates that the Trp(2313)-His(2315) segment is an important constituent of the membrane-binding motif and provides a model to understand the molecular mechanism of the C2 domain membrane interaction.
-
==Disease==
+
Trp2313-His2315 of factor VIII C2 domain is involved in membrane binding: structure of a complex between the C2 domain and an inhibitor of membrane binding.,Liu Z, Lin L, Yuan C, Nicolaes GA, Chen L, Meehan EJ, Furie B, Furie B, Huang M J Biol Chem. 2010 Mar 19;285(12):8824-9. Epub 2010 Jan 20. PMID:20089867<ref>PMID:20089867</ref>
-
[[http://www.uniprot.org/uniprot/FA8_HUMAN FA8_HUMAN]] Defects in F8 are the cause of hemophilia A (HEMA) [MIM:[http://omim.org/entry/306700 306700]]. A disorder of blood coagulation characterized by a permanent tendency to hemorrhage. About 50% of patients have severe hemophilia resulting in frequent spontaneous bleeding into joints, muscles and internal organs. Less severe forms are characterized by bleeding after trauma or surgery. Note=Of particular interest for the understanding of the function of F8 is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8 in their plasma (at least 30% of normal), but the protein is non-functional; i.e. the F8 activity is much less than the plasma protein level. CRM-reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.<ref>PMID:3012775</ref><ref>PMID:3122181</ref><ref>PMID:2833855</ref><ref>PMID:2835904</ref><ref>PMID:2499363</ref><ref>PMID:2506948</ref><ref>PMID:2510835</ref><ref>PMID:2495245</ref><ref>PMID:2498882</ref><ref>PMID:2104766</ref><ref>PMID:2105106</ref><ref>PMID:1973901</ref><ref>PMID:2105906</ref><ref>PMID:2106480</ref><ref>PMID:2107542</ref><ref>PMID:1908817</ref><ref>PMID:1908096</ref><ref>PMID:1851341</ref><ref>PMID:1356412</ref><ref>PMID:1639429</ref><ref>PMID:1349567</ref><ref>PMID:1301194</ref><ref>PMID:1301932</ref><ref>PMID:1301960</ref><ref>PMID:8449505</ref><ref>PMID:8322269</ref><ref>PMID:7579394</ref><ref>PMID:7794769</ref><ref>PMID:7759074</ref><ref>PMID:8644728</ref><ref>PMID:8639447</ref><ref>PMID:8759905</ref><ref>PMID:9029040</ref><ref>PMID:9326186</ref><ref>PMID:9341862</ref><ref>PMID:9886318</ref><ref>PMID:9450898</ref><ref>PMID:10215414</ref><ref>PMID:9603440</ref><ref>PMID:9452104</ref><ref>PMID:9792405</ref><ref>PMID:9829908</ref><ref>PMID:9569180</ref><ref>PMID:9569189</ref><ref>PMID:10554831</ref><ref>PMID:10338101</ref><ref>PMID:10408784</ref><ref>PMID:10404764</ref><ref>PMID:10910910</ref><ref>PMID:10910913</ref><ref>PMID:10691849</ref><ref>PMID:10886198</ref><ref>PMID:10800171</ref><ref>PMID:10896236</ref><ref>PMID:10612839</ref><ref>PMID:11410838</ref><ref>PMID:11298607</ref><ref>PMID:11442643</ref><ref>PMID:11442647</ref><ref>PMID:11554935</ref><ref>PMID:11748850</ref><ref>PMID:11341489</ref><ref>PMID:12351418</ref><ref>PMID:12406074</ref><ref>PMID:12199686</ref><ref>PMID:11857744</ref><ref>PMID:12203998</ref><ref>PMID:12325022</ref><ref>PMID:11858487</ref><ref>PMID:12195713</ref><ref>PMID:12930394</ref><ref>PMID:12871415</ref><ref>PMID:12614369</ref><ref>PMID:15682412</ref><ref>PMID:15810915</ref><ref>PMID:16805874</ref><ref>PMID:18184865</ref><ref>PMID:21371196</ref>
+
-
==Function==
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[http://www.uniprot.org/uniprot/FA8_HUMAN FA8_HUMAN]] Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa.
+
</div>
-
 
+
-
==About this Structure==
+
-
[[3hnb]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3HNB OCA].
+
==See Also==
==See Also==
*[[Factor VIII|Factor VIII]]
*[[Factor VIII|Factor VIII]]
-
 
+
== References ==
-
==Reference==
+
<references/>
-
<ref group="xtra">PMID:020089867</ref><references group="xtra"/><references/>
+
__TOC__
 +
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
-
[[Category: Liu, Z.]]
+
[[Category: Liu, Z]]
-
[[Category: Yuan, C.]]
+
[[Category: Yuan, C]]
[[Category: Blood clotting]]
[[Category: Blood clotting]]
[[Category: Small molecule inhibitor/blood clotting]]
[[Category: Small molecule inhibitor/blood clotting]]

Revision as of 16:20, 18 December 2014

Factor VIII Trp2313-His2315 segment is involved in membrane binding as shown by crystal structure of complex between factor VIII C2 domain and an inhibitor

3hnb, resolution 1.15Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/3hnb"
Personal tools